Packaging capacity and stability of human adenovirus type 5 vectors.
about
Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.The adenovirus genome contributes to the structural stability of the virionThe role of chromatin in adenoviral vector functionAdenovirus-Mediated Expression of the p14 Fusion-Associated Small Transmembrane Protein Promotes Cancer Cell Fusion and Apoptosis In Vitro but Does Not Provide Therapeutic Efficacy in a Xenograft Mouse Model of CancerAn adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.Virus reconstituted from infectious bacterial artificial chromosome (BAC)-cloned murine gammaherpesvirus 68 acquires wild-type properties in vivo only after excision of BAC vector sequences.General strategy for broadening adenovirus tropism.Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coliDirected evolution generates a novel oncolytic virus for the treatment of colon cancerVector and helper genome rearrangements occur during production of helper-dependent adenoviral vectors.Autoexcision of bacterial artificial chromosome facilitated by terminal repeat-mediated homologous recombination: a novel approach for generating traceless genetic mutants of herpesvirusesThe effect of N- or C-terminal alterations of the connector of bacteriophage phi29 DNA packaging motor on procapsid assembly, pRNA binding, and DNA packagingSystematic excision of vector sequences from the BAC-cloned herpesvirus genome during virus reconstitution.Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors.Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration abilityDNA as therapeutics; an update.The adenovirus major core protein VII is dispensable for virion assembly but is essential for lytic infection.Viral genome segmentation can result from a trade-off between genetic content and particle stability.Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer.Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing.Adenoviral vector driven by a minimal Rad51 promoter is selective for p53-deficient tumor cells.Viral and nonviral delivery systems for gene deliveryCharacterization of human adenovirus 35 and derivation of complex vectorsRescue, propagation, and partial purification of a helper virus-dependent adenovirus vectorReplication-competent infectious hepatitis B virus vectors carrying substantially sized transgenes by redesigned viral polymerase translation.The promise of gene therapy in gastrointestinal and liver diseases.Distribution of DNA-condensing protein complexes in the adenovirus core.Survivin-targeting Artificial MicroRNAs Mediated by Adenovirus Suppress Tumor Activity in Cancer Cells and Xenograft ModelsAn efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3.Adenovirus-mediated expression of a voltage-gated potassium channel in vitro (rat cardiac myocytes) and in vivo (rat liver). A novel strategy for modifying excitabilitySite-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression.Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus.A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging.Real-time sensing and discrimination of single chemicals using the channel of phi29 DNA packaging nanomotor.A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal.Induction of a Protective Heterosubtypic Immune Response Against the Influenza Virus by using Recombinant Adenoviral Vectors Expressing Hemagglutinin of the Influenza H5 VirusConditionally replicating adenoviruses for cancer treatment.Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression.The α2 helix in the DNA ligase IV BRCT-1 domain is required for targeted degradation of ligase IV during adenovirus infection.Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector.
P2860
Q24533013-59BD99A6-ED7A-4550-AF74-39E15DC42CA4Q26825101-70F7FDA2-04F1-4562-A4DC-A44017080540Q27004695-0FC5F555-194F-4220-AB13-0E06362BE01AQ27317286-A62822E3-3292-4BF6-8354-3AC7E7E66D6DQ27469506-20D9E307-54A5-4B84-AF6F-33B88DF23E7EQ30668724-94E444C4-65A9-4436-920F-93FAAF083142Q31002814-EE4CABAF-D06C-40E9-B926-3D1064163476Q33252754-41AA2EE7-D604-45C5-9BBF-63A0722E4259Q33344440-F2E0FD29-6E58-4C25-9B2E-99244F16C707Q33586303-DEF111A2-ADDE-407C-BFB1-60AA251667CFQ33676526-1D1B5491-5289-49CD-811A-3646ADC85DE1Q33795162-99ADD036-EF8F-4D2C-A136-492B12DC540CQ33818345-BC65F060-9C56-471F-8734-7DBF74877D28Q33818929-EEE7EC47-2D34-427A-9CB3-FB56A7A0FCABQ33834104-AB381A99-1A74-4C1F-8125-A9B14506262EQ33836499-1873ED81-8FB4-4639-9BAD-B0CC5BF7C451Q33853916-6DEBE3FB-36FD-49DC-B7E1-AE3C2C93090EQ33855631-96C8FD7B-BE58-46B2-B228-E03CC1859122Q33904270-1CF8727D-9F10-4EC4-984D-200DCC18172CQ34058399-285F7FDE-F43A-4C01-9A08-D00E6190B728Q34103307-098A8D86-8C96-41F3-B8AC-554A1FF14E1DQ34315475-44DE9FCB-53A4-4F34-B77D-9FED5A6831A3Q34322336-3EF07661-C5C3-46BA-8AED-66189FFFB96DQ34385773-4E78B538-5BC1-4728-B98D-049F894A22ECQ34669990-92DED02D-63F6-4F56-83B4-5C027E507F9EQ35090229-F803E136-72C5-4B41-920C-89304B22CCA7Q35562051-97D7D2B0-2405-44D1-B93D-57A1D1A4BE86Q35694238-9073E430-0F8E-4F72-B900-B578DC09DD06Q35748116-6EC20F9D-B445-4331-99DC-C5D725A062FBQ35753549-4DCC125B-2D59-4088-A2ED-699B133BD713Q35843809-9F8A6BDD-00CA-431F-8740-E0C4A08FA263Q35861543-D6D419B0-0634-427F-BB46-53521F17EF60Q35881805-D2DBDFDD-40E8-47C5-8993-6569D14BE316Q35914607-EBB1E04F-56D3-432F-9492-DED24618E227Q35915922-3984A76D-94B6-46A5-A903-2D58DBF5899FQ35944309-E97DB8E5-4BD0-4D54-8157-E9A64FCED041Q35967313-6D48E401-1A2B-4207-948C-CA49C1DD1757Q36051171-6766DE27-8EE4-499C-8E7E-CEAAB4D47211Q36057815-A117BBFD-873D-45CC-AE7A-B9FA6D8BA9E1Q36071414-F7F53043-D249-42CF-B98B-7EC60CB32AF4
P2860
Packaging capacity and stability of human adenovirus type 5 vectors.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Packaging capacity and stability of human adenovirus type 5 vectors.
@ast
Packaging capacity and stability of human adenovirus type 5 vectors.
@en
type
label
Packaging capacity and stability of human adenovirus type 5 vectors.
@ast
Packaging capacity and stability of human adenovirus type 5 vectors.
@en
prefLabel
Packaging capacity and stability of human adenovirus type 5 vectors.
@ast
Packaging capacity and stability of human adenovirus type 5 vectors.
@en
P2093
P2860
P1433
P1476
Packaging capacity and stability of human adenovirus type 5 vectors
@en
P2093
P2860
P304
P407
P577
1993-10-01T00:00:00Z